Working… Menu

Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03473600
Recruitment Status : Unknown
Verified March 2018 by Noura Ali, Assiut University.
Recruitment status was:  Not yet recruiting
First Posted : March 22, 2018
Last Update Posted : March 22, 2018
Information provided by (Responsible Party):
Noura Ali, Assiut University

Brief Summary:

Alopecia areata is the most frequent cause of inflammation-induced hair loss with prevalence from 0.1 to 0.2%. It has no age nor sex predilection .

Clinically, alopecia areata presents as a well-circumscribed patch of sudden hair loss. It affects any hair bearing area. The most common affected site is the scalp. Based on site and extent, AA can be classified into; diffuse, multi-locularis, mono-locularis, totalis, universalis, and ophiasis.

Condition or disease Intervention/treatment Phase
Alopecia Areata Procedure: Cryotherapy Drug: Triamcinolone acetonide injection Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation
Estimated Study Start Date : November 2018
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : September 2019

Arm Intervention/treatment
Experimental: study group
•The first group (20 patients) will be treated with cryotherapy using liquid nitrogen spray, two cycles each one 3-5 seconds, one session every two weeks, for three months.
Procedure: Cryotherapy
Liquid Nitrogen spray

Active Comparator: control group
•The second group (20 patients) will be treated with intralesional injection of 4mg/ml/ session of triamcinolone-acetonide, it will be injected into deep dermis or upper subcutaneous tissue using a 0.5-inch long 30-gauge needle at multiple sites, 1 cm apart and 0.1 ml into each site, once every three weeks, for three months, using insulin syringes.
Drug: Triamcinolone acetonide injection
Intralesional Triamcinolone Acetonide injection

Primary Outcome Measures :
  1. The incidence of patietns with hair regrowth [ Time Frame: 3 months ]
    measuring severity of alopecia tool score and dermoscopic examination

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age >12 years.
  • Both sexes will be included.
  • Newly diagnosed cases.

Exclusion Criteria:

  • Children < 12 years.
  • Pregnancy and lactation.
  • Patients with active scalp infection.
  • Patients with cold sensitivity (regarding the first group).
  • Any newly onset medical systemic illness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03473600

Layout table for location contacts
Contact: Hanan Ahmed Morsy, Assistant professor 01064447881
Contact: Aya Youssef Mohamed, Lecturer 01013244819

Layout table for location information
Faculty of medicine
Assiut, Egypt, 71111
Contact: Aya Youssef, Lecturer    01013244819      
Sponsors and Collaborators
Assiut University

Layout table for additonal information
Responsible Party: Noura Ali, Principal Investigator, Assiut University Identifier: NCT03473600    
Other Study ID Numbers: CVILCsAA
First Posted: March 22, 2018    Key Record Dates
Last Update Posted: March 22, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alopecia Areata
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical
Triamcinolone Acetonide
Triamcinolone hexacetonide
Triamcinolone diacetate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action